Overview

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine what effects the drug Abraxane has on bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborator:
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel